By Elric Langton | 22nd December 2021
There has been a lot of confusion and misunderstanding around the launch of SkinBioTherapeutics Plc (SBTX) βsoft launchβ of its landmark commercial product, AxisBiotix Ps, designed to alleviate mild to moderate Psoriasis. This event was soon followed by the sell-off, closely followed by the conspiracy the market knows something retail investors do not. Uhm, really! I am not going down this rabbit hole again because I have already ventured down it, and the destination has not changed.